LOGIN 

 

JOIN

 

RENEW

 

CME/MOC

Journal Club

HomeMembersAssemblies and SectionsAssembliesRespiratory Cell and Molecular BiologyJournal Club ▶ Drug Development and Clinical Trials in the COVID-19 Era
Drug Development and Clinical Trials in the COVID-19 Era

Webinar date: Friday, June 26, 2020 12:00pm EDT


This webinar was sponsored by the Assembly on Respiratory Cell and Molecular Biology (RCMB) Innovation and Entrepreneurial Working Group 

Presenters:

Louise Hecker, PhD, Associate Professor, University of Arizona, Founder and Chief Scientific Officer (CSO) of Fibronox

Naftali Kaminski, MD, Boehringer-Ingelheim Endowed Professor of Internal Medicine 
Chief of Pulmonary, Critical Care and Sleep Medicine Department of Medicine, Yale School of Medicine 

Erica Park, PharmD, Senior Director, Clinical Development, and Monica Sandberg, PhD, Head of Regulatory Affairs, Pliant Therapeutics, San Francisco, CA

Panelists:

Tim Watkins, MD MSc, Executive Director, Clinical Research, Respiratory Disease Area Lead Inflammation Therapeutics, Gilead Sciences Inc

Toby Maher, MD/PhD, Professor of Medicine and Director of Interstitial Lung Disease, Keck School of Medicine, University of Southern California, Los Angeles, USA

Colin Reisner, MD, Head, Respiratory Global Medicine, AstraZeneca; CEO, Pearl Therapeutics, Inc

David Morris, MD, Operating Partner, Novartis Venture Fund and Chief Medical Officer of Enterprise Therapeutics

Alan H Cohen, MD, Vice President of Global Medical Affairs, Eidos Therapeutics, San Francisco, CA

Moderator: 

Milica Vukmirovic, PhD, Michael DeGroote Innovation, Commercialization, and Entrepreneurship Fellow, McMaster University; Innovation and Commercialization Consultant, St. Joseph’s Research Institute